Investors Target Myriad Genetics Following Sharp Guidance Cut

The scrutiny centers on whether management provided misleading financial information during the company’s May 5, 2026, earnings call. At that time, Chief Financial Officer Ben Wheeler explicitly confirmed annual revenue targets of $860 million to $880 million, while CEO Samraat Raha projected sequential growth for the second quarter. These assurances collapsed when Q2 revenue reached only $190.7 million, falling significantly below both the previous quarter’s $200.4 million and consensus analyst estimates of $206 million.

Levi & Korsinsky is now evaluating potential securities fraud claims on behalf of shareholders who suffered losses following the guidance revision. The firm, a perennial member of the ISS Top 50 securities litigation list, is collecting brokerage records to determine if the May reaffirmation of financial targets constituted a material misrepresentation. Investors who held or purchased the stock during this period are encouraged to contact the firm to review their eligibility for recovery, regardless of whether they currently retain their shares.